文献速递头颈外科

诱导化疗对晚期头颈癌生存的影响:美国国家癌症数据库分析

Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis.
PubMed 文献 · Head Neck · 2017-03-16

该研究基于美国国家癌症数据库,纳入8031例接受放疗和化疗的T4或N2b至N3期头颈癌患者,比较诱导化疗与同步化疗的生存差异。多因素分析显示诱导化疗组生存与同步化疗组无显著差异(HR 0.96,95%CI 0.88-1.05,p=0.35),但诱导化疗组接受<66 Gy放疗剂量的比值更高(p<0.01)。结论认为诱导化疗无生存优势且更可能接受较低放疗剂量。

要点

  • 诱导化疗组与同步化疗组生存无显著差异(HR 0.96,95%CI 0.88-1.05,p=0.35)。
  • 诱导化疗组接受<66 Gy放疗剂量的比值高于同步化疗组(p<0.01)。
  • 晚期疾病亚组分析中诱导化疗同样未见生存优势。

核心结论

  • 诱导化疗受试者较同步化疗受试者无生存优势,但更可能接受较低放疗剂量。

研究设计与样本

  • 基于美国国家癌症数据库的分析,纳入8031例接受放疗和化疗的T4或N2b至N3期头颈癌患者,分为诱导化疗组和同步化疗组,采用多因素分析探讨治疗与生存的关联并识别放疗剂量的预测因素。

主要发现

  • 多因素分析纳入社会人口学和临床变量后,诱导化疗组生存与同步化疗组无显著差异(HR 0.96,95%CI 0.88-1.05,p=0.35)。
  • 晚期疾病亚组分析中诱导化疗同样未见生存优势。
  • 多因素分析显示诱导化疗组患者接受<66 Gy放疗剂量的比值增加(p<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adding induction chemotherapy to concurrent chemotherapy and radiotherapy (RT) has generally not improved the overall survival (OS) in randomized trials of patients with head and neck cancer. This failure may stem from inadequate power or inappropriate patient selection, prompting this National Cancer Data Base analysis. METHODS: 8031 patients with T4 or N2b to N3 disease undergoing RT and chemotherapy were divided into induction chemotherapy and concurrent chemotherapy cohorts. Multivariate analysis was used to explore the association of treatment with survival and to identify predictors of radiation dose. RESULTS: On multivariate analysis incorporating sociodemographic and clinical variables, survival of the induction chemotherapy cohort was not significantly different from that of the concurrent cohort (hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.88-1.05; p = .35), nor on subgroup analyses of advanced disease. Multivariate analysis demonstrated increased odds of receiving <66 Gy among the patients in the induction chemotherapy cohort (p < .01). CONCLUSION: Induction chemotherapy subjects experienced no survival advantage over concurrent chemotherapy subjects but were more likely to receive lower RT doses. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1113-1121, 2017.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Stokes WA, Amini A, Jones BL, et al. Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis. Head Neck. 2017. PMID: 28301079. doi:10.1002/hed.24739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。